Related references
Note: Only part of the references are listed.Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation Status
Matthias Schneider et al.
PHARMACEUTICALS (2021)
Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma
Matthias Schneider et al.
NEURO-ONCOLOGY (2021)
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
Ulrich Herrlinger et al.
LANCET (2019)
Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide
Anna-Laura Potthoff et al.
CANCERS (2019)
Electrical and synaptic integration of glioma into neural circuits
Humsa S. Venkatesh et al.
NATURE (2019)
Glutamatergic synaptic input to glioma cells drives brain tumour progression
Varun Venkataramani et al.
NATURE (2019)
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial
Johannes Weller et al.
LANCET ONCOLOGY (2019)
Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas
Sophie Weil et al.
NEURO-ONCOLOGY (2017)
Life beyond a diagnosis of glioblastoma: a systematic review of the literature
L. Gately et al.
JOURNAL OF CANCER SURVIVORSHIP (2017)
Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide
Susan F. Murphy et al.
CANCER RESEARCH (2016)
Gap Junction Blockers: An Overview of their Effects on Induced Seizures in Animal Models
Joaquin Manjarrez-Marmolejo et al.
CURRENT NEUROPHARMACOLOGY (2016)
Phase I trial of dovitinib (TKI258) in recurrent glioblastoma
Niklas Schaefer et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Michael Weller et al.
CLINICAL CANCER RESEARCH (2015)
Brain tumour cells interconnect to a functional and resistant network
Matthias Osswald et al.
NATURE (2015)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43
J. L. Munoz et al.
CELL DEATH & DISEASE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Meclofenamic acid blocks the gap junction communication between the retinal pigment epithelial cells
N. Ning et al.
HUMAN & EXPERIMENTAL TOXICOLOGY (2013)
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
James R. Perry et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Share Paper
